DE60317565D1 - Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden - Google Patents
Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-ligandenInfo
- Publication number
- DE60317565D1 DE60317565D1 DE60317565T DE60317565T DE60317565D1 DE 60317565 D1 DE60317565 D1 DE 60317565D1 DE 60317565 T DE60317565 T DE 60317565T DE 60317565 T DE60317565 T DE 60317565T DE 60317565 D1 DE60317565 D1 DE 60317565D1
- Authority
- DE
- Germany
- Prior art keywords
- insulin
- pharmaceutical compositions
- hexamer
- ligands
- hexamer ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201991 | 2002-12-20 | ||
| DK200201991 | 2002-12-20 | ||
| US43938203P | 2003-01-10 | 2003-01-10 | |
| US439382P | 2003-01-10 | ||
| PCT/DK2003/000931 WO2004056347A2 (en) | 2002-12-20 | 2003-12-22 | Pharmaceutical compositions comprising insulin and legends of insulin hexamer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60317565D1 true DE60317565D1 (de) | 2007-12-27 |
| DE60317565T2 DE60317565T2 (de) | 2008-09-11 |
Family
ID=32683719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60317565T Expired - Fee Related DE60317565T2 (de) | 2002-12-20 | 2003-12-22 | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1585541B1 (de) |
| JP (1) | JP2006516966A (de) |
| AT (1) | ATE378063T1 (de) |
| AU (1) | AU2003291972A1 (de) |
| DE (1) | DE60317565T2 (de) |
| ES (1) | ES2297227T3 (de) |
| WO (1) | WO2004056347A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037927B2 (en) * | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| KR20070029247A (ko) | 2004-07-08 | 2007-03-13 | 노보 노르디스크 에이/에스 | 폴리펩티드 연장 태그 |
| WO2006005683A1 (en) * | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| US20080280814A1 (en) * | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
| DE102005022182A1 (de) * | 2005-05-09 | 2006-11-16 | Combinature Biopharm Ag | Modulatoren der PDZ-Domäne |
| TW200800978A (en) * | 2006-03-23 | 2008-01-01 | Otsuka Pharma Co Ltd | Carbazole compound |
| JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| EP3083609B1 (de) * | 2013-12-19 | 2018-08-15 | Merck Sharp & Dohme Corp. | Hiv-proteasehemmer |
| EP3229807A4 (de) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Hemmer von zellulärer nekrose und zugehörige verfahren |
| ES2935722T3 (es) * | 2017-07-28 | 2023-03-09 | Novartis Ag | Derivados de indol y usos de los mismos |
| CN112351975A (zh) * | 2018-03-16 | 2021-02-09 | 俄克拉何马大学董事会 | 过氧化物酶体增殖物活化受体α的激动剂和使用方法 |
| US20230129364A1 (en) * | 2019-12-26 | 2023-04-27 | Yonsei University, University - Industry Foundation (UIF) | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same |
| CN113929588B (zh) * | 2020-06-29 | 2023-08-15 | 沈阳化工研究院有限公司 | 一种合成4-氨基甲基苯甲酸的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| EP1396272A1 (de) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose |
| HUP0401492A3 (en) * | 2001-09-14 | 2008-05-28 | Novo Nordisk As | Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa |
-
2003
- 2003-12-22 WO PCT/DK2003/000931 patent/WO2004056347A2/en active IP Right Grant
- 2003-12-22 AU AU2003291972A patent/AU2003291972A1/en not_active Abandoned
- 2003-12-22 ES ES03767488T patent/ES2297227T3/es not_active Expired - Lifetime
- 2003-12-22 EP EP03767488A patent/EP1585541B1/de not_active Expired - Lifetime
- 2003-12-22 AT AT03767488T patent/ATE378063T1/de not_active IP Right Cessation
- 2003-12-22 DE DE60317565T patent/DE60317565T2/de not_active Expired - Fee Related
- 2003-12-22 JP JP2005502527A patent/JP2006516966A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1585541B1 (de) | 2007-11-14 |
| EP1585541A2 (de) | 2005-10-19 |
| ATE378063T1 (de) | 2007-11-15 |
| ES2297227T3 (es) | 2008-05-01 |
| JP2006516966A (ja) | 2006-07-13 |
| AU2003291972A8 (en) | 2004-07-14 |
| AU2003291972A1 (en) | 2004-07-14 |
| DE60317565T2 (de) | 2008-09-11 |
| WO2004056347A2 (en) | 2004-07-08 |
| WO2004056347A3 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101293A2 (hu) | AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása | |
| DE60317565D1 (de) | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden | |
| DE60224284D1 (de) | Stabile formulierung von modifiziertem glp-1 | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| BR0210078A (pt) | Composto, uso do mesmo, e, formulação farmacêutica | |
| GEP20063741B (en) | Nonaryl-Heterocyclic NMDA/NR2B Antagonists | |
| MXPA04002404A (es) | Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. | |
| SE0301700D0 (sv) | Novel compounds | |
| NO20054555L (no) | Farmasoytiske preparater som omfatter syrestabilisert insulin | |
| DE69931930D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
| EA200301250A1 (ru) | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры | |
| DE50206657D1 (de) | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
| TW200604197A (en) | New compounds | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| SE0101038D0 (sv) | Novel compounds | |
| CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
| SE0102716D0 (sv) | Novel compounds | |
| NO20073914L (no) | Biologisk aktive peptider | |
| SE0303280D0 (sv) | Novel compounds | |
| MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
| SE0302755D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |